Section Arrow
TYRA.NASDAQ
- Tyra Biosciences
Quotes are at least 15-min delayed:2025/01/11 17:24 EST
Last
 15.2
-0.77 (-4.82%)
Day High 
15.71 
Prev. Close
15.97 
1-M High
16.8988 
Volume 
418.89K 
Bid
14.1
Ask
16.78
Day Low
14.545 
Open
15.71 
1-M Low
13.2705 
Market Cap 
808.13M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 14.87 
20-SMA 14.91 
50-SMA 15.66 
52-W High 29.6 
52-W Low 12.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.61/-2.40
Enterprise Value
814.35M
Balance Sheet
Book Value Per Share
7.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 17:24 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.